ACTG 219: PEDIATRIC LATE OUTCOMES PROTOCOL

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。这项研究旨在寻找药物治疗对生长、发育、长期生存和生活质量的长期影响。本研究的目的是跟踪正在或曾经参加过儿科ACTG研究的儿童和青少年。这包括所有感染人类免疫缺陷病毒（HIV）的母亲所生的婴儿，这些母亲在怀孕期间参加了ACTG药物研究，接受了抗HIV疫苗的婴儿或儿童，以及参加了由儿科艾滋病基金会赞助的长期幸存者研究（LTS）的儿童和青少年。所有孩子都将被跟踪到21岁生日。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is looking for any long-term effects of drug therapy on growth, development, long-term survival, and quality of life. The purpose of this study is to follow children and teenagers who are or have been in pediatric ACTG research studies. This includes all babies born to human immunodeficiency virus (HIV) infected mothers who were enrolled in an ACTG drug study when they were pregnant, infants or children who received anti-HIV vaccines, and children and teenagers enrolled in the Long Term Survivors study (LTS) sponsored by the Pediatric AIDS Foundation. All children will be followed until their 21st birthday.